Methods Of Treatment Of Keloid Using An Anti-VEGF Agent

Abstract

Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (NSAID) to a subject.

What is claimed is: 
     
         1 . A method for treating keloid recurrence, the method comprising administering (1) an anti-VEGF agent to a site where a keloid has been removed from a subject. 
     
     
         2 . The method of  claim 1 , wherein the anti-VEGF agent is an antibody or small molecule inhibitor of VEGF signaling. 
     
     
         3 . The method of  claim 1 , wherein the anti-VEGF agent is the antibody bevacizumab. 
     
     
         4 . The method according to  claim 3 , wherein the bevacizumab is administered at a dose of 10 mg. 
     
     
         5 . The method of  claim 1 , wherein the anti-VEGF agent is administered by injection or topically. 
     
     
         6 . The method of  claim 5 , wherein the anti-VEGF agent is injected at or adjacent to a site of new blood vessel growth at the site of keloid removal. 
     
     
         7 . The method of  claim 1 , further comprising administering to the site (2) an anti-inflammatory steroid or (3) a non-steroidal anti-inflammatory drug (NSAID), or both. 
     
     
         8 . The method of  claim 1 , wherein the anti-inflammatory steroid is applied topically, systemically, or by injection to the site of keloid removal. 
     
     
         9 . The method of  claim 1 , wherein the anti-inflammatory steroid is alclometasone, diflorasone, fluocinonide, or prednicarbate. 
     
     
         10 . The method of  claim 1 , wherein the NSAID is diclofenac. 
     
     
         11 . The method of  claim 1 , further comprising administering to the site one or more subsequent administrations of one or more of an anti-VEGF agent, an anti-inflammatory steroid, and an NSAID.